HR Execs on the Move

CHR Hansen

www.chr-hansen.com

 
Chr. Hansen is a leading manufacturer of natural food color, with companies in over thirty countries, and color factories and application centers all over the world. Among the company's clients are some of the market leaders within the food and beverage
  • Number of Employees: 25-100
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details

Similar Companies

The Harvard Drug Group

The Harvard Drug Group is a Livonia, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Infinity Pharmaceuticals Inc

Infinity Pharmaceuticals is an innovative cancer drug discovery and development company that leverages its strength in small molecule drug technologies to bring important new medicines to patients.

Pediatric Associates

Pediatric Associates has been caring for infants, children and adolescents since 1955. Pediatric Associates opened its first office in Hollywood, FL. Since then, our physicians have cared for four generations of families with our first patients now bringing their children, grandchildren and great-grandchildren to our practice. From South Florida to Tampa and Jacksonville, across the state of Florida and now across the country, Pediatric Associates has more than 200 locations nationwide.

Ripple Therapeutics

The Ripple Therapeutics Epidel® technology is founded on a discovery that drugs can be engineered into controlled release materials without the use of polymers or excipients. The proprietary prodrugs are new chemical entities (NCEs) that have unique properties that allow them to be processed into standalone drug delivery implants (e.g. intravitreal implants, micro/nanoparticles, etc.) or as coatings on medical devices. Ripple Therapeutics implants and coatings are made up entirely from the prodrug without a polymeric carrier to control the implant or drug release properties. The implants and coatings undergo surface erosion to give zero order drug release profiles and are highly engineerable (e.g. different forms, shapes, and sizes) to tailor drug dose and duration for the specific indication of interest. The flexibility in molecular design results in drug doses that are within the therapeutic window, delivering the right amount of drug for the right amount of time. This has the potential to improve patient safety and clinical outcomes.